Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

March 23, 2016

Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs.

March 11, 2016

Doctors Without Borders/Médecins Sans Frontières (MSF) started treating hepatitis C in Karachi, Pakistan's Machar Colony slum not just because of the area's poor health system, but also because many people there couldn't otherwise afford testing and treatment. By providing care at a primary health care clinic, patients can access free diagnosis and quality treatment without having to travel to a hospital, a journey that for many is prohibitively expensive. The current project is a pilot to show that this model of decentralized care can be effective.

June 19, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) has learned that the Chinese patent office has just denied Gilead Science’s request for a key patent on the hepatitis C drug sofosbuvir. This drug, together with other antivirals, is the backbone of several newer, more effective curative treatments for hepatitis C, yet is exorbitantly priced in many countries, restricting access for people who need it. Hepatitis C is a global public health crisis, with at least 150 million people living with the disease, and 350,000-500,000 people die each year from complications of it.

September 15, 2014

 

On September 15, Gilead Sciences is expected to announce agreements with a handful of Indian pharmaceutical manufacturers to produce and sell generic versions of two new Hepatitis C drugs—sofosbuvir and ledipasvir. Approximately 180 million people live with Hepatitis C today, with 350,000 people dying annually of the disease.